CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL:Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF